357 related articles for article (PubMed ID: 27194534)
1. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.
Ausoni S; Boscolo-Rizzo P; Singh B; Da Mosto MC; Spinato G; Tirelli G; Spinato R; Azzarello G
Cancer Metastasis Rev; 2016 Sep; 35(3):413-26. PubMed ID: 27194534
[TBL] [Abstract][Full Text] [Related]
2. Molecular Aspects of Head and Neck Cancer Therapy.
Puram SV; Rocco JW
Hematol Oncol Clin North Am; 2015 Dec; 29(6):971-92. PubMed ID: 26568543
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.
Schmitz S; Machiels JP
Curr Treat Options Oncol; 2016 Jul; 17(7):37. PubMed ID: 27262711
[TBL] [Abstract][Full Text] [Related]
4. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
Bowles DW; McDermott JD; Jimeno A
Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
[TBL] [Abstract][Full Text] [Related]
5. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.
Hammerman PS; Hayes DN; Grandis JR
Cancer Discov; 2015 Mar; 5(3):239-44. PubMed ID: 25643909
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Factor Kappa B: A Potential Target to Persecute Head and Neck Cancer.
Monisha J; Roy NK; Bordoloi D; Kumar A; Golla R; Kotoky J; Padmavathi G; Kunnumakkara AB
Curr Drug Targets; 2017; 18(2):232-253. PubMed ID: 26844566
[TBL] [Abstract][Full Text] [Related]
8. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
9. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
10. New promising molecular targets in head and neck squamous cell carcinoma.
Bauman JE; Michel LS; Chung CH
Curr Opin Oncol; 2012 May; 24(3):235-42. PubMed ID: 22327839
[TBL] [Abstract][Full Text] [Related]
11. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
Hartmann S; Bhola NE; Grandis JR
Clin Cancer Res; 2016 Aug; 22(16):4005-13. PubMed ID: 27370607
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Isaacsson Velho PH; Castro G; Chung CH
Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
[TBL] [Abstract][Full Text] [Related]
13. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
Pollock NI; Grandis JR
Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
[TBL] [Abstract][Full Text] [Related]
14. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
15. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
16. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.
Markovic A; Chung CH
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1149-59. PubMed ID: 23098115
[TBL] [Abstract][Full Text] [Related]
17. Impact of targeting insulin-like growth factor signaling in head and neck cancers.
Limesand KH; Chibly AM; Fribley A
Growth Horm IGF Res; 2013 Oct; 23(5):135-40. PubMed ID: 23816396
[TBL] [Abstract][Full Text] [Related]
18. Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.
Boscolo-Rizzo P; Da Mosto MC; Rampazzo E; Giunco S; Del Mistro A; Menegaldo A; Baboci L; Mantovani M; Tirelli G; De Rossi A
Cancer Metastasis Rev; 2016 Sep; 35(3):457-74. PubMed ID: 27501725
[TBL] [Abstract][Full Text] [Related]
19. Targeting Cellular Metabolism Modulates Head and Neck Oncogenesis.
Hsieh YT; Chen YF; Lin SC; Chang KW; Li WC
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31416244
[TBL] [Abstract][Full Text] [Related]
20. Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.
Liu CJ; Chang WJ; Chen CY; Sun FJ; Cheng HW; Chen TY; Lin SC; Li WC
Oncotarget; 2015 Oct; 6(30):29268-84. PubMed ID: 26337468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
